Journal of
Public Health and Epidemiology

  • Abbreviation: J. Public Health Epidemiol.
  • Language: English
  • ISSN: 2141-2316
  • DOI: 10.5897/JPHE
  • Start Year: 2009
  • Published Articles: 616

Full Length Research Paper

Genotypic variation, demographic characteristics and risk factors of hepatitis C virus in Scotland

Iveren Winifred Nyinoh
  • Iveren Winifred Nyinoh
  • Department of Biological Sciences, Benue State University, 970001, Makurdi, Benue State, Nigeria.
  • Google Scholar


  •  Received: 04 May 2018
  •  Accepted: 24 May 2018
  •  Published: 31 July 2018

References

Alter MJ (2007). Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology, 13:2436-2441.
Crossref

 

Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G (2014). Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World Journal of Gastroenterology, 20(29):9633-9652.
Crossref

 
 

Averhoff FM, Glass N, Holtzman D (2012). Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Clinical Infectious Diseases, 55 Suppl 1:S10-15. doi: 10.1093/cid/cis361.
Crossref

 
 

Balogun MA, Murphy N, Nunn S, Grant A, Andrews NJ, Teo CG, Ramsay ME, Parry JV (2009). Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics. Epidemiology and Infection 137:980-987.
Crossref

 
 

Balogun MA, Ramsay ME, Parry JV, Donovan L, Andrews NJ, Newham JA, McGarrigle C, Harris KA, Teo CG (2003). A national survey of genitourinary medicine clinic attenders provides little evidence of sexual transmission of hepatitis C virus infection. Sexually Transmitted Infections 79(4):301-306.
Crossref

 
 

Benvegnù L, Gios M, Boccato S, Alberti A (2004). Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53(5):744-749.
Crossref

 
 

Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN (2015). Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology, 149(6):1471-1482.
Crossref

 
 

Bhamidimarri KR, Satapathy SK, Martin P (2017). Hepatitis C Virus and Liver Transplantation. Journal of Gastroenterology and Hepatology, 13(4):214-220.

 
 

Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T (2013). Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World Journal of Hepatology, 5(9):496-504.
Crossref

 
 

Carney K, Dhalla S, Aytaman A, Tenner CT, Francois F (2013). Association of tattooing and hepatitis C virus infection: a multicenter case-control study. Hepatology, 57(6):2117-2123.
Crossref

 
 

Davis GL, Lau JY (1997). Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology, 26(3 Suppl 1):122S-127S.
Crossref

 
 

Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, McIntyre N, Simmonds P (1994). Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 19(1):13-18.
Crossref

 
 

Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME, HCV National Register Steering Group (2007). Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? Journal of Viral Hepatitis, 14(3):213-220.
Crossref

 
 

Harris KA, Gilham C, Mortimer PP, Teo CG (1999). The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. Journal of Medical Virology 58(2):127-31.
Crossref

 
 

Hauri AM, Armstrong GL, Hutin Y (2004). The global burden of disease attributable to contaminated injections given in health care settings. International Journal of STD & AIDS, 15:7-16.
Crossref

 
 

Health Protection Scotland (HPS), University of the West of Scotland (UWS) (2008) The Needle Exchange Surveillance Initiative (NESI):

 
 

Health Protection Scotland (HPS), University of the West of Scotland (UWS) (2012) Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV and injecting risk behaviours among people who

 
 

Hutchinson SJ, Roy KM, Wadd S, Bird SM, Taylor A, Anderson E, Shaw L, Codere G, Goldberg DJ (2006). Hepatitis C Virus in Scotland: epidemiological review and public health challenges. Scottish Medical Journal 51(2):8-15.
Crossref

 
 

Jauncey M, Micallef JM, Gilmour S, Amin J, White PA, Rawlinson W, Kaldor JM, van Beek I, Dore GJ (2004). Clearance of hepatitis C virus after newly acquired infection in injection drug users. The Journal of Infectious Diseases 190(7):1270-1274.
Crossref

 
 

Josephson F, Swedish Consensus Group (2016). Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. Infectious Diseases (Lond) 48(4):251-261
Crossref

 
 

Kamal SM, Naseer IA (2008). Hepatitis C Genotype 4: What we know and don't yet know (Reviews). Hepatology, 47(4).
Crossref

 
 

Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El–Serag HB (2011). Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 140(4):1182-1188. doi: 10.1053/j.gastro.2010.12.032.
Crossref

 
 

Kershenobich D, Razavi HA, Sánchez‐Avila JF, Bessone F, Coelho HS, Dagher L, Gonçales FL, Quiroz JF, Rodriguez‐Perez F, Rosado B, Wallace C (2011). Trends and projections of hepatitis C virus epidemiology in Latin America. Liver International, 31 Suppl 2:18-29.
Crossref

 
 

Lagging M, Wejstål R, Norkrans G, Karlström O, Aleman S, Weiland O, Castedal M, Lauer GM, Walker BD (2001). Hepatitis C virus infection. New England Journal of Medicine 345(1):41-52.
Crossref

 
 

Lowe GD (1987). Haemophilia, blood products and HIV infection. Scottish Medical Journal 32(4):109-11.
Crossref

 
 

Madhava V, Burgess C, Drucker E (2002). Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. The Lancet Infectious Diseases 2:293-302.
Crossref

 
 

Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2015). Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1):77-87.
Crossref

 
 

Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L (2011). Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378:571-583.
Crossref

 
 

Nguyen MH, Keeffe EB (2005). Prevalence and treatment of hepatitis C virus genotypes 4, 5 & 6. Clinical Gastroenterology and Hepatology 3 Suppl 2: S97-S101.
Crossref

 
 

Palmateer NE, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, McAllister G, Gunson R, Hutchinson SJ (2014). Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One 11;9(8):e104515. doi: 10.1371/journal.pone. 0104515.

 
 

Patel K, Muir AJ, McHutchison JG (2006). Diagnosis and treatment of chronic hepatitis C infection. British Medical Journal 332(7548):1013-1017.
Crossref

 
 

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 45(4):529-38. https://doi.org/10.1016/j.jhep.2006.05.013.
Crossref

 
 

Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C (2016). Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infectious Agents and Cancer (1):53.
Crossref

 
 

Prati D (2006). Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. Journal of Hepatology 45:607-616.
Crossref

 
 

Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR (2010). Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. Eastern Mediterranean Health Journal 16 suppl: S15-23.
Crossref

 
 

Roy KM, Hutchinson SJ, Wadd s, Taylor A, Cameron SO, Burns S, Molyneaux P, McIntyre PG, Goldberg DJ (2007). Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiology and Infection 135(3):433-442.
Crossref

 
 

Salemovic D, Pesic-Pavlovic I, Jevtovic D, Bojovic K, Ranin J, Brmbolic B, Stanojevic M (2017). Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Archives of Medical Science 13(3):652-658
Crossref

 
 

Seeff LB (2002). Natural history of chronic hepatitis C. Hepatology 36(5 Suppl 1):S35-46.

 
 

Shaw L, Taylor A, Roy KM, Cameron SO, Burns S, Molyneaux, McIntyre P, Codere G, Goldberg DJ (2003). Establishment of a database of a diagnosed HCV-infected persons in Scotland. Communicable Disease and Public Health 6:305-310.

 
 

Shepard CW, Finelli L, Alter MJ (2005). Global epidemiology of hepatitis C virus infection. The Lancet Infectious Diseases 5(9):558-67.
Crossref

 
 

Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, AlOmair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M (2011). A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver International 31(s2):61-80. doi:10.1111/j.1478-3231.2011.02540.x.
Crossref

 
 

Smith DB, Becher P, Bukh J, Gould EA, Meyers G, Monath T, Muerhoff AS, Pletnev A, Rico-Hesse R, Stapleton JT, Simmonds P (2016). Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family. Journal of General Virology 97(11):2894-2907.
Crossref

 
 

Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM., Stapleton JT., et al (2014). Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59: 318-327.
Crossref

 
 

Thong VD, Akkarathamrongsin S, Poovorawan K, Tangkijvanich P, Poovorawan Y. Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication (2014). World Journal of Gastroenterology 20(11):2927-2940.
Crossref

 
 

Tohme RA, Holmberg SD (2012). Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clinical Infectious Diseases 54(8):1167-78.
Crossref

 
 

Toyoda H, Kumada T, Tada T, Yama T, Mizuno K (2017). Significance of day-1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct- acting antiviral therapy. Journal of Gastroenterology and Hepatology 33(6):1264-1270.
Crossref

 
 

Watson JP, Brind AM, Chapman CE, Bates CL, Gould FK, Johnson SJ, Burt AD, Ferguson J, Simmonds P, Bassendine MF (1996). Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut 38(2):269-276.
Crossref

 
 

Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, Hatzakis A, Prins M, Vickerman P, Lazarus JV, et al (2014). Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One.9:e103345.
Crossref

 
 

Williams IT, Bell BP, Kuhnert W, Alter MJ (2011). Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006. Archives of Internal Medicine 171:242-248.
Crossref

 
 

World Health Organization (2015). Hepatitis C Fact sheet N°164. Available online at http://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c.

 
 

Yasin T, Riley TR, Schreibman IR (2011). Current treatment of choice for chronic hepatitis C infection. Infection and Drug Resistance 4:11-18.

 
 

Yee BE, Nguyen NH, Zhang B, Lin D, Vutien P, Wong CR, Lutchman GA, Nguyen MH (2015). Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis. BMJ Open Gastroenterology, 2(1):e000049.
Crossref